Micro- and nano-robots are engineered agents at micro- and nanoscale dimensions that can target therapy, sense conditions, manipulate matter, or release drugs when triggered. As of September 2026, their strongest medical case is localized, image-guided delivery or sensing in controlled settings—not autonomous machines that routinely diagnose or cure disease inside people.
Table of Contents
- What are micro- and nano-robots?
- How do they move and deliver drugs?
- What has been demonstrated in animals and vessel models?
- What limits real-world medical use?
- What should readers believe—and what should they ask?
What are micro- and nano-robots?
A micro-robot operates at the micrometer scale, while a nano-robot works at the nanometer scale. Designs may combine a small body with magnetic particles, drug payloads, sensors, or structures that respond to an external signal. Magnetic systems commonly use iron-oxide nanoparticles and external magnetic fields.
Researchers also use acoustic, optical, electrical, chemical, or biological propulsion methods, according to Elsevier's 2026 review in *Biochemical and Biophysical Research Communications*. The label "nano-robot" does not automatically mean a fully autonomous machine. Some systems are better understood as remotely controlled particles or miniature carriers whose movement, sensing, or drug release depends on equipment outside the body.
How do they move and deliver drugs?
External magnetic fields can pull, rotate, or steer a robot through fluid. Other systems respond to ultrasound, light, electric fields, chemical reactions, or biological processes. The propulsion method determines what control equipment, energy source, and safety questions the design needs.
Self-propelled systems require particular scrutiny. Their fuel, reaction products, biodegradability, and biocompatibility can affect whether a promising laboratory design is suitable for living tissue, according to the NCBI-indexed review *Micro and nanorobot-based drug delivery*. Drug release may occur when a robot reaches a target or receives a trigger. In practical terms, this could concentrate treatment in a selected location, but the system still needs reliable navigation, imaging, release control, clearance, and safety evidence.
What has been demonstrated in animals and vessel models?
An ETH Zurich-led platform used gelatin-based magnetic microrobots in human-vessel models, pigs, and sheep cerebrospinal fluid. The robots released drugs under imaging guidance, and ETH Zurich reported correct delivery in more than 95% of tested model cases in its 13 November 2025 research release. These results show that guided delivery can work across increasingly realistic test environments.
They do not establish that the platform is safe or effective for patients; the researchers identified human clinical trials as the next goal. A February 2026 translational framework likewise reported that most untethered milli- and microrobots remained laboratory proof-of-concepts. For these systems, moving through a fluid is only one milestone; clinical integration remains the larger challenge.
What limits real-world medical use?
Human-scale magnetic guidance becomes harder as the target moves deeper into the body. An August 2026 study found that operating in the 5–30 millitesla and 1–30 hertz range could require sub-kilogram magnets for some limb or intracranial targets, but more than 30 kilograms for deep thoracic access. That equipment burden affects procedure design, imaging, positioning, and where treatment could take place.
A robot that works in a small laboratory vessel may need substantially different hardware and control methods inside a human body. Regulation adds another layer. The FDA has no single regulatory definition of "nanomaterial," but it may consider engineered materials up to 1,000 nanometers when size creates specific properties. Nanomaterial drugs must still meet ordinary requirements for safety, efficacy, quality, and current good manufacturing practice under FDA guidance on drug products containing nanomaterials.
What should readers believe—and what should they ask?
The most defensible current use case is localized, image-guided delivery or sensing in a controlled medical setting. Claims about routine autonomous nanobots that diagnose or cure disease inside people need human-trial and regulatory evidence before they can support a treatment decision.
When evaluating a reported system, check: For now, the meaningful question is not simply whether a robot can move. It is whether the complete system can deliver a measurable benefit safely, repeatedly, and with equipment suitable for clinical care.
- Whether testing used a dish, a vessel model, animals, or people.
- How the robot is powered, steered, tracked, and recovered.
- Whether the payload releases at the intended site.
- What happens to the robot, fuel, reaction products, and materials afterward.
- Whether a regulator has evaluated the specific product and intended use.
